<DOC>
	<DOCNO>NCT02671799</DOCNO>
	<brief_summary>This prospective , multi-center , single-arm study evaluate VenTouch System treatment moderate moderate-severe functional mitral valve regurgitation [ FMR ] .</brief_summary>
	<brief_title>Evaluation Minimally Invasive VenTouch™ System Treatment Functional Mitral Valve Regurgitation ( FMR )</brief_title>
	<detailed_description>This trial prospective , multi-center , single-arm First-In-Man Continuation study evaluate safety efficacy VenTouch System treatment subject functional MR enrol 15 subject diagnose Grade 3-4 functional mitral valve regurgitation . The duration study follow-up 36 month time therapy adjustment . Data trial may utilize support CE study Europe and/or pilot IDE study U.S . Follow-up test perform 1 month , 3 month , 6 month , 12 , 24 , 36 month post-therapy adjustment .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>1 . Adults ≥18 year age 2 . Symptomatic FMR grade moderately severe severe ( 3 4 ) structurally normal leaflet ( preferably echocardiographic evidence EROA &gt; 0.20 cm2 ) 3 . NYHA Class II IV 4 . Left Ventricular Ejection Fraction ( LVEF ) 20 % 50 % 5 . Treatment optimal guidelinedirected medical therapy heart failure least 30 day . Subjects must receive beta blocker 3 month ACEI ARB one month unless , investigator 's opinion , subject intolerant beta blocker , ACEI ARB . Beta blocker ACEI ( ARB ) dose stable one month prior study entry . Stable define 100 % increase 50 % decrease dose . 6 . Subjects Class I indication CRT implant accord current guideline CRT implant prior entry study . Subjects exist CRT implant may include study implant place least 90 day . 7 . Left Ventricular End Diastolic Diameter ( LVEDD ) 55 80 mm determine transthoracic echocardiography . 8 . Subject willing available return study followup 9 . Subject legal representative understands provide sign informed consent participation study 10 . Acceptance subject trial enrollment review subject baseline data Study Selection Committee 1 . Life expectancy le 12 month due condition cardiac status 2 . Identified need cardiovascular surgery 3 . Untreated clinically significant coronary artery disease 4 . Any procedure , condition cardiac anatomy may impact compromise pericardial space ( e.g . prior mitral valve surgery , CABG , epicardial pacing lead , pericarditis , procedure involve pericardial access ) 5 . Percutaneous coronary intervention , acute coronary syndrome ( e.g . STEMI nonSTEMI myocardial infarction , unstable angina ) clinically significant cardiac event ( e.g hypotension , syncope , arrhythmia , embolism , heart failure exacerbation hospitalization ) within 30 day enrollment 6 . Thoracic cardiac surgery contraindication ( e.g. , acute respiratory distress , endocarditis , myocarditis , pericarditis ) 7 . Significant structural abnormality mitral valve ( e.g . flail leaflet , rupture elongated chordae , prolapse valve , perforate valve leaflet , significant calcification annulus , calcification leaflet restrict motion ) 8 . Severe symptomatic carotid stenosis 9 . Severe sustain pulmonary hypertension , define rest pulmonary artery systolic ( PAS ) pressure great equal 70 mm Hg 10 . Physical evidence rightsided congestive heart failure echocardiographic evidence moderate severe right ventricular dysfunction 11 . Hypotension ( systolic pressure &lt; 90mm Hg ) 12 . Hypertrophic cardiomyopathy , restrictive cardiomyopathy , structural heart disease cause heart failure dilate cardiomyopathy 13 . UNOS status 1 heart transplantation 14 . Creatinine &gt; 2.5 mg/dL ( 221 µmol/L ) and/or renal failure require dialysis 15 . Active systemic infection bleed 16 . Autoimmune disorder and/or use immune suppression therapy 17 . Females pregnant ( documented HCG beta pregnancy test female childbearing age ) lactate 18 . Currently enrol another investigational drug device study IntraOperative 1 . Subjects heart size outside offer VenTouch System size range 2 . Significant structural abnormality mitral valve ( e.g . flail leaflet , rupture elongated chordae , prolapse valve , perforate valve leaflet , significant calcification annulus , calcification leaflet restrict motion ) 3 . Signs/indications ischemia 4 . Intraoperative coronary angiography demonstrate compression coronary artery reduction coronary blood flow due VenTouch implant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>